Host prostaglandin EP3 receptor signaling relevant to tumor-associated lymphangiogenesis

Biomedicine and Pharmacotherapy

Volumn 64, Issue 2, 2010, Pages 101-106

  Kubo, Hidefumi ^a   Hosono, Kanako ^a,b   Suzuki, Tatsunori ^a,b   Ogawa, Yasufumi ^a   Kato, Hiroshi ^a   Kamata, Hiroki ^a   Ito, Yoshiya ^a   Amano, Hideki ^a,b   Kato, Tetsuki ^a,b   Sakagami, Hiroyuki ^a   Hayashi, Izumi ^a   Sugimoto, Yukihiko ^c   Narumiya, Shuh ^d   Watanabe, Masahiko ^a   Majima, Masataka ^a,b  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KITASATO UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d KYOTO UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

Cancer; COX 2; Eicosanoid; VEGF C; VEGFR 3

Indexed keywords

CELECOXIB; MESSENGER RNA; PODOPLANIN; PROSTAGLANDIN E1; PROSTAGLANDIN E2; PROSTAGLANDIN E3; VASCULOTROPIN RECEPTOR 3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; GENE EXPRESSION; KNOCKOUT MOUSE; LEWIS CARCINOMA; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; MALE; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; TREATMENT DURATION; TUMOR VASCULARIZATION; TUMOR VOLUME; WILD TYPE;

ANIMALS; CELL LINE, TUMOR; CYCLOOXYGENASE 2 INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; LYMPHANGIOGENESIS; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, KNOCKOUT; NEOPLASMS; PYRAZOLES; RECEPTORS, PROSTAGLANDIN E; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SULFONAMIDES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77349125367     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2009.04.039     Document Type: Article

References (33)

1. Alitalo K., Tammela T., Petrova T.V. Lymphangiogenesis in development and human disease. Nature 2005, 438:946-953.
2. Tobler N.E., Detmar M. Tumor and lymph node lymphangiogenesis - impact on cancer metastasis. J Leukoc Biol 2006, 80:691-696.
3. Oh S.J., Jeltsch M.M., Birkenhäger R., et al. VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev Biol 1997, 188:96-109.
4. Jeltsch M., Kaipainen A., Joukov V., et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 1997, 276:1423-1425.
5. Veikkola T., Jussila L., Makinen T., et al. Signaling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J 2001, 20:1223-1231.
6. Kaipainen A., Korhonen J., Mustonen T., et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A 1995, 92:3566-3570.
7. Skobe M., Hawighorst T., Jackson D.G., et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001, 7:192-198.
8. Stacker S.A., Caesar C., Baldwin M.E., et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 2001, 7:186-191.
9. Stacker S.A., Achen M.G., Jussila L., et al. Lymphangiogenesis and cancer metastasis. Nature Rev. Cancer 2002, 2:573-583.
10. Giovannucci E., Egan K.M., Hunter D.J., et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995, 333:609-614.
11. Gupta R.A., Dubois R.N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001, 1:11-21.
12. Majima M., Amano H., Hayashi I. Prostanoid receptor signaling relevant to tumor growth and angiogenesis. Trends Pharmacol Sci 2003, 24:524-529.
13. Amano H., Hayashi I., Endo H., et al. Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J Exp Med 2003, 197:221-232.
14. Su J.L., Shih J.Y., Yen M.L., et al. Cyclooxygenase-2 induces EP1- and HER-2/Neudependent vascular endothelial growth factor-C up-regulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma. Cancer Res 2004, 64:554-564.
15. von Rahden B.H., Stein H.J., Puhringer F., et al. Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinoma. Cancer Res 2005, 5038-5044.
16. Timoshenko A.V., Chakraborty C., Wagner G.F., et al. COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer. Br J Cancer 2006, 94:1154-1163.
17. Narumiya S., Sugimoto Y., Ushikubi F. Prostanoid receptors: structures, properties, and function. Physiol Rev 1999, 79:1193-1226.
18. Fujita M., Hayashi I., Yamashina S., et al. Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth. Carcinogenesis 2005, 26:271-279.
19. Toda M., Suzuki T., Hosono K., et al. Neuronal system-dependent facilitation of tumor angiogenesis and tumor growth by calcitonin gene-related peptide. Proc Natl Acad Sci U S A 2008, 105:13550-13555.
20. Schacht V., Ramirez M.I., Hong Y.K., et al. T1alpha/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema. EMBO J 2003, 22:3546-3556.
21. Ordóñez N.G. Podoplanin: a novel diagnostic immunohistochemical marker. Adv Anat Pathol 2006, 13:83-88.
22. Kamoshita E., Ikeda Y., Fujita M., et al. Recruitment of a prostaglandin E receptor subtype, EP3-expressing bone marrow cells is crucial in wound-induced angiogenesis. Am J Pathol 2006, 169:1458-1472.
23. Romano M., Claria J. Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy. FASEB J 2003, 17:1986-9195.
24. Iwata C., Kano M.R., Komuro A., et al. Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via reduction of lymphangiogenesis. Cancer Res 2007, 67:10181-10189.
25. Barnes N.L., Warnberg F., Farnie G., et al. Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer. Br J Cancer 2007, 96:575-582.
26. He Y., Kozaki K., Karpanen T., et al. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst 2002, 94:819-825.
27. Lin J., Lalani A.S., Harding T.C., et al. Inhibition of lymphogenous metastasis using adeno-associated virus mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res 2005, 65:6901-6909.
28. Shimizu K., Kubo H., Yamaguchi K., et al. Suppression of VEGFR-3 signaling inhibits lymph node metastasis in gastric cancer. Cancer Sci 2004, 95:328-333.
29. Roberts N., Kloos B., Cassella M., et al. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res 2006, 66:2650-2657.
30. Chen Z., Varney M.L., Backora M.W., et al. Down-regulation of vascular endothelial cell growth factor-C expression using small interfering RNA vectors in mammary tumors inhibits tumor lymphangiogenesis and spontaneous metastasis and enhances survival. Cancer Res 2005, 65:9004-9011.
31. He X.W., Liu T., Chen Y.X., et al. Calcium carbonate nanoparticle delivering vascular endothelial growth factor-C siRNA effectively inhibits lymphangiogenesis and growth of gastric cancer in vivo. Cancer Gene Ther 2008, 15:193-202.
32. Chilov D., Kukk E., Taira S., et al. Genomic organization of human and mouse genes for vascular endothelial growth factor C. J Biol Chem 1997, 272:25176-25183.
33. Fulton A.M., Ma X., Kundu N. Targeting prostaglandin E EP receptors to inhibit metastasis. Cancer Res 2006, 66:9794-9797.